Key Clinical Findings on the Efficacy, Safety Profile and Immunogenicity of Biosimilar SB11
Expert retina specialists discuss the efficacy and safety data of the ranibizumab biosimilar, SB11 [BYOOVIZ ▼ (ranibizumab)], and explore the practical implications of biosimilars in the broader real-world context.
This program is intended for health care providers in UK, Canada, and Switzerland. This program focuses on EU regulations and may differ from other jurisdictions.
In UK, Canada, and Switzerland, the SmPC and regulatory requirements may differ from those of the FDA and EMA.
UK (GB&NI) BYOOVIZ Prescribing Information
Please refer to the PI here.
Adverse events should be reported. Reporting forms and Information can be found at https://yellowcard.mhra.gov.uk/. Adverse events should also be reported to Biogen Idec Limited: TEL: +44(0)20 360 886 22. Email: Medinfo.europe@biogen.com
Canada BYOOVIZ Prescribing Information
Consult the product monograph at 00072313.PDF (hres.ca) for contraindications, warnings, precautions, adverse reactions, interactions, dosing, and conditions of clinical use. The product monograph is also available through our medical department. Call us at 1-866-477-3462.
Visit the Web page on Adverse Reaction Reporting (https://www.biogen.ca/en-ca/company/contact-us.html?accKey=2) for information on how to report online, by mail or by fax; or calling toll-free at 1-866-234-2345.
Switzerland BYOOVIZ Prescribing Information
BYOOVIZ, Dispensing Category B.
▼ This medicinal product is subject to additional monitoring. For further information see information for professionals of BYOOVIZ on www.swissmedicinfo.ch.
MA-holder: Samsung Bioepis CH GmbH, Lucerne
To report an adverse event, please email us at medinfo.europe@biogen.com or call 0848 000 022.
Biogen- 223326 March 2024
